The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab by Shima, Yoshihito et al.
Concise report
The skin of patients with systemic sclerosis
softened during the treatment with anti-IL-6
receptor antibody tocilizumab
Yoshihito Shima
1, Yusuke Kuwahara
1, Hiroyuki Murota
2, Shun Kitaba
2,
Mari Kawai
1, Toru Hirano
1, Junsuke Arimitsu
1, Masashi Narazaki
1,
Keisuke Hagihara
1, Atsushi Ogata
1, Ichiro Katayama
2, Ichiro Kawase
1,
Tadamitsu Kishimoto
3 and Toshio Tanaka
1
Abstract
Objective. SSc is an autoimmune disease characterized by fibrosis of the skin and internal organs.
Although the aetiology remains uncertain, many reports have suggested that IL-6 is involved in SSc
pathogenesis. Tocilizumab, an anti-IL-6 receptor antibody, is an anti-arthritis medicine that works through
the blockade of IL-6 functions. To examine the effect of tocilizumab on SSc, we administered tocilizumab
to two SSc patients.
Methods. Two dcSSc patients were administered tocilizumab at 8mg/kg once a month for 6 months. One
patient had pulmonary fibrosis assessed by CT and spirometry, and the other had chronic renal failure
caused by scleroderma renal crisis. Their skin condition was monitored with a Vesmeter and the modified
Rodnan total skin score (mRTSS). Skin biopsies were obtained before and after the tocilizumab treatment
to investigate the histological changes.
Results. After tocilizumab treatment, both patients showed softening of the skin with reductions of
50.7 and 55.7% in the total z-score of Vesmeter hardness and 51.9 and 23.0% in the mRTSS,
respectively. Histological examination showed thinning of the collagen fibre bundles in the dermis. The
creatinine clearance in the patient with chronic renal failure improved from 38 to 55ml/min. However, the
fibrotic changes in the lung in the other patient remained unchanged.
Conclusions. In the two cases of SSc that we report here, softening of the skin was observed during the
treatment with tocilizumab.
Key words: Systemic sclerosis, Scleroderma, Interleukin-6, Anti-IL-6 receptor antibody, Tocilizumab, Skin
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Introduction
SSc is a disease of uncertain aetiology, and is character-
ized by fibrotic changes in not only the skin but also
internal organs. Currently, immunosuppressants, e.g.
MTX, are recommended for the treatment of SSc and
CYC has also been proved to be effective for interstitial
lung diseases and skin thickening [1]. However, the bene-
fits are modest and no highly effective therapy exists.
MTX sometimes causes adverse pulmonary reactions.
Consequently, it is difficult to use MTX for SSc patients
with lung involvement. A new therapeutic method is there-
fore required to improve the condition of the skin or in-
ternal organs that have become harder than normal. To
this end, IL-6, one of the pro-inflammatory cytokines, has
been implicated in the pathogenesis of SSc. IL-6 expres-
sion is reportedly high in both the skin and serum of SSc
patients [2], and its elevation depends on the skin score
[3]. Tocilizumab, an anti-IL-6 receptor antibody, blocks
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RA and Castleman disease have been verified [4]. If IL-6
contributes to the pathological condition of SSc, tocilizu-
mab therapy may be effective for this disease. To clarify
the effects of tocilizumab on SSc, we administered tocili-
zumab to two patients with refractory states of SSc.
Patients and methods
Two patients underwent tocilizumab treatment with the
approval of the Ethics Committee of Osaka University
Hospital after providing informed consent. The patients
met the classification criteria for SSc established by the
ARA in 1980 [5]. Tocilizumab was administered at 8mg/kg
every 4 weeks, which is equal to the dosage used for RA.
Before this study, the skin condition was evaluated at
17 locations according to the modified Rodnan skin
score using a Vesmeter by a single examiner [6]. The
modified Rodnan total skin score (mRTSS) was calculated
at the same time [7]. Each crude Vesmeter hardness was
converted to a z-score, which represents the standardized
degree of deviation from the normal average, because
normal skin hardness varies between body sites. The
normal values necessary to calculate z-score were
referred from our previous study [6]. For identification of
histological changes, skin biopsies were obtained from
the left forearm before tocilizumab administration.
Spirometric evaluation was conducted to assess the
restrictive ventilatory impairment as well as lung CT to
determine pulmonary fibrosis and an oesophageal radio-
graphic contrast study to evaluate lower oesophageal
dilatation. A HAQ for disability index (HAQ-DI) was used
to evaluate the activities of daily living [8]. The skin biopsy,
spirometry, chest CT and oesophagus radiographic con-
trast study were performed again after the tocilizumab
treatment. Paraffin-embedded biopsy tissues were sub-
jected to haematoxylin and eosin staining as well as
immunohistochemical staining using mouse anti-human
a-smooth muscle actin (aSMA) antibody 1A4 (DAKO
Cytomation, Glostrup, Denmark) to evaluate the number
of myofibroblasts using an enzyme-labelled antibody
method [9,10]. Briefly, PBS supplemented with 2% BSA
was used as a blocking reagent, a 1:50 dilution of the
anti-aSMA mAb was used as the primary antibody and a
peroxidase-conjugated goat anti-mouse/rabbit immuno-
globulin antibody (DAKO Cytomation) was used as the
secondary antibody.
Patient 1 was a 42-year-old man who had been suffer-
ing from swelling of the fingers and RP since 2005.
Treatment with prednisolone at 0.5mg/kg/day was
initiated, but his skin sclerosis continued to spread from
his hands to his forearms, upper arms and feet.
Serological examinations found neither anti-topo I nor
ACAs. ANA was positive with homogeneous and speckled
stained patterns. The patient was diagnosed with dcSSc,
and because of the severe skin sclerosis (maximum
mRTSS: 32), he was treated with ciclosporin at
150mg/day plus predonisolone at 10mg/day in 2006.
His serum creatinine level suddenly increased from
0.7 to 2.7mg/dl within 1 month in association with
an elevation in blood pressure from 144/84 to
160/104mmHg in 2007. Laboratory data showed neither
fragmented red blood cells nor ANCAs. Daily urine volume
was not reduced, but urine analysis showed positive for
protein and occult blood. The plasma level of rennin
activity in the morning showed 51.9ng/ml/h (normal:
0.5–2.0ng/ml/h). Consequently, administration of telmi-
sartan at 80mg/day was started to suppress his blood
pressure in view of a diagnosis of scleroderma renal
crisis. Before the first administration of tocilizumab, spir-
ometry and chest CT excluded the presence of pulmonary
fibrosis, while a radiographic contrast study of the oe-
sophagus demonstrated lower oesophageal dilatation.
The serum creatinine level (1.40mg/dl) and creatinine
clearance (38ml/min) indicated a decrease in renal func-
tion, although proteinuria and urine occult blood were
negative when started. The peripheral blood cell count
and urinalysis were within normal limits. The CRP level
was <0.04mg/dl (normal: <0.2mg/dl) and the serum
IL-6 concentration was 6.19pg/ml (normal: <4.0pg/ml).
Administration of prednisolone at 10mg/day and telmisar-
tan at 80mg/day was continued. Patient 2 was a
57-year-old woman who had been suffering from RP
and swelling of the fingers since 2004. She became
aware of dyspnoea on effort and sclerotic changes in
the skin of the bilateral hands and forearms as well as
the chest. Serological examination was positive for
anti-topo I antibodies and ANA with homogeneous and
speckled stained patterns. She was diagnosed with SSc
and treatment with prednisolone at 10mg/day was
initiated in 2005. However, skin sclerosis spread to her
face and upper arms, consistent with diffuse cutaneous
disease. It continued to worsen, even though ultraviolet
A treatment with 1% psoralen lotion was started in
2007. Owing to the progression of skin sclerosis, the pa-
tient was admitted to our hospital. Before initiation of toci-
lizumab therapy, her peripheral blood cell count, urinalysis
and serum creatinine level were confirmed to be within
the normal limits. The CRP level was <0.04mg/dl
(normal: <0.2mg/dl) and the serum IL-6 concentration
was 2.77pg/ml. A CT study revealed patchy infiltrates
associated with ground-glass opacities in the bilateral
lower lung areas. Spirometry showed that the vital cap-
acity (VC) was 71.6% of the predicted value, forced ex-
piratory volume in 1s as a percentage of forced VC (FVC)
[forced expiratory volume (FEV) 1.0%] was 84.5% and
the diffusing capacity for carbon monoxide (DLco) was
35.5%. No lower oesophageal dilatation or retention of
contrast agent was observed in a radiographic contrast
study. Administration of prednisolone at 10mg/day was
continued.
Results
During the 6-month tocilizumab therapy, both the total
z-score of Vesmeter hardness and mRTSS decreased
(Fig. 1). In Patient 1, the total z-score of Vesmeter hard-
ness decreased from 50.1 to 24.7 (50.7% reduction) and
mRTSS decreased from 27 to 13 (51.9% reduction). In
Patient 2, the total z-score of Vesmeter hardness
www.rheumatology.oxfordjournals.org 2409
Tocilizumab therapy for systemic sclerosisdecreased from 67.5 to 29.9 (55.7% reduction) and
mRTSS decreased from 26 to 20 (23% reduction). The
decrease in HAQ-DI was observed in both patients as
follows: from 0.375 to 0.125 in Patient 1 and from 1.50
to 1.00 in Patient 2. As a result of skin softening, joint
mobility also improved. The distance between the palm
and third fingertip during forceful gripping was shortened
from 17mm (right) and 13mm (left) to 0mm on each side
in Patient 1, and from 30mm (right) and 23mm (left) to
12mm and 0mm, respectively, in Patient 2. The distance
between the lips during forceful mouth opening became
vertically elongated from 30mm to 50mm in Patient 2.
Although histological studies did not show any marked
changes in the thickness of the dermis, thinning of the
collagen fibre bundles in the dermis was observed
(Fig. 2A–D). Immunohistochemical staining for aSMA
showed positivity in several cells in the dermis and vas-
cular walls, and the number of positive cells in the dermis
decreased after the treatment in both patients (Fig. 2E–H).
Patient 1 showed kidney involvement, and the serum
creatinine level and clearance improved from 1.40 to
1.18mg/dl and from 38 to 55ml/min, respectively, during
the treatment period, although they had showed only
minor changes from 1.31 to 1.40mg/dl and from 45 to
38ml/min during the preceding 6 months. Patient 2
did not show kidney involvement and the kidney
function did not change during the treatment period.
The oesophageal radiographic contrast studies did not
show any pronounced changes, although a minor im-
provement in contraction after the contrast agent had
passed was observed in Patient 1. Patient 2 had lung in-
volvement, and re-examination by chest CT showed the
same degree of pulmonary fibrosis as in the first examin-
ation. Re-examination of the %VC and %DLco showed
that they remained low at 69.8 and 35.5%, respectively.
Adverse reactions were not observed during the periods
of this study. Other laboratory data including peripheral
blood cell counts, aminotransferases, cholesterols or pro-
tein did not show marked change. Patient 1 showed
leucocytosis and hypertriglyceridaemia before the study,
but they did not show significant change.
Discussion
This is the first report on treating SSc patients with tocili-
zumab. Although the role of IL-6 in SSc remains unclear,
many studies have reported that abnormalities in IL-6 are
related to SSc. For example, the culture supernatants of
peripheral blood mononuclear cells from patients with
SSc were reported to contain higher concentrations of
IL-6 than those from normal subjects [11]. Similarly, the
culture supernatants of skin tissues from SSc patients
were also found to contain elevated IL-6 levels [12].
Furthermore, the serum IL-6 concentrations of SSc pa-
tients were reported to be increased and the degree of
the increase was dependent on the skin thickness score
[2, 3]. Although the patients described here did not show
marked elevation of CRP or serum IL-6, overproduction of
IL-6 by the affected skin even in the case of SSc patients
with normal serum IL-6 levels was reported [12]. It has
already been reported that anti-IL-6 antibody suppressed
pro-collagen production in fibroblasts from SSc patients
[13]. Therefore, tocilizumab, an anti-IL-6 receptor antibody
that blocks the function of IL-6, is worth studying for the
clinical effect on SSc.
Histological examination revealed changes in the
collagen fibre bundles, and immunohistochemical staining
showed a decrease of aSMA-positive cells in the dermis.
aSMA-positive myofibroblasts have been reported to
exhibit abundant production of collagen [9], and their
number in the dermis was reported to be correlated with
skin hardness [10]. IL-6 may affect the production of
extracellular matrix through down-regulation of collagen-
producing cells.
The interaction between IL-6 and internal organs has
been the subject of discussion [14]. Patient 1 did not
show marked change in his oesophageal involvement,
and Patient 2 did not show any improvement in her
pulmonary fibrosis, although both patients showed an
improving tendency for their skin. In this study, the vas-
cular involvement including RP was not evaluated. To
clarify these points, the present study needs to be ex-
tended to other patients with involvement of internal
organs.
The Vesmeter is a new device that can measure
the physical properties of skin. We previously reported
FIG.1Clinical courses of Patient 1 (A) and Patient 2 (B).
(*): total z-score of Vesmeter hardness; ( ): mRTSS.
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of patients with SSc [6]. Vesmeter hardness is well
correlated with the hardness standards authorized
by the American Society for Testing and Materials. We
used the Vesmeter for serial evaluations of the skin to
assess the drug efficacy, and the results demonstrated
that this machine was useful for such studies. As
shown in Fig. 1, the total z-score of Vesmeter hardness
tended to be more highly sensitive than mRTSS. This
is the first report of a clinical follow-up study using the
Vesmeter.
In this report, we have described two patients with SSc
who showed skin softening during the treatment with
tocilizumab. Further controlled studies are necessary to
properly evaluate its efficacy.
Rheumatology key messages
. The skin of patients with SSc softened during
treatment with tocilizumab.
. Vesmeter was useful for assessment of therapy for
SSc.
FIG.2(A, B) Haematoxylin and eosin-stained skin biopsy specimens from the left arm of Patient 1 obtained before
tocilizumab therapy (A) and after administration of the therapy for 6 months (B). Thinning of the collagen fibre bundles in
the dermis is observed. A representative example is indicated by the difference between the distances from a to b and c
to d. (C, D) Haematoxylin and eosin-stained skin biopsy specimens from the left arm of Patient 2 obtained before
tocilizumab therapy (C) and after administration of the therapy for 6 months (D). (Original magnification  100.) (E–G)
Immunohistochemical staining with an anti-aSMA antibody of skin biopsy sections obtained from Patient 1 before (E) and
after (F) the tocilizumab therapy, and from Patient 2 before (G) and after (H) the tocilizumab therapy. aSMA-positive cells
outside the vascular wall are indicated by (!). (Original magnification  200.)
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